MA52987A - Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak - Google Patents

Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak

Info

Publication number
MA52987A
MA52987A MA052987A MA52987A MA52987A MA 52987 A MA52987 A MA 52987A MA 052987 A MA052987 A MA 052987A MA 52987 A MA52987 A MA 52987A MA 52987 A MA52987 A MA 52987A
Authority
MA
Morocco
Prior art keywords
pyrazin
pyrazolo
derivatives
jak inhibitors
jak
Prior art date
Application number
MA052987A
Other languages
English (en)
Inventor
Matthew Frank Brown
Alpay DERMENCI
Andrew Fensome
Brian Stephen Gerstenberger
Matthew Merrill Hayward
Dafydd Rhys Owen
Stephen Wayne Wright
Li Huang Xing
Xiaojing Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA52987A publication Critical patent/MA52987A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052987A 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak MA52987A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662299130P 2016-02-24 2016-02-24

Publications (1)

Publication Number Publication Date
MA52987A true MA52987A (fr) 2021-04-28

Family

ID=58054385

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052987A MA52987A (fr) 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA43668A MA43668B1 (fr) 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43668A MA43668B1 (fr) 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak

Country Status (45)

Country Link
US (4) US10144738B2 (fr)
EP (2) EP3712153B1 (fr)
JP (1) JP6505956B2 (fr)
KR (1) KR102128671B1 (fr)
CN (1) CN109071546B (fr)
AR (1) AR107714A1 (fr)
AU (1) AU2017222417B2 (fr)
CA (1) CA2958490C (fr)
CL (1) CL2018002358A1 (fr)
CO (1) CO2018008799A2 (fr)
CR (1) CR20180372A (fr)
CU (1) CU24511B1 (fr)
CY (1) CY1122949T1 (fr)
DK (1) DK3419978T3 (fr)
DO (1) DOP2018000187A (fr)
EA (1) EA035036B1 (fr)
EC (1) ECSP18072109A (fr)
ES (1) ES2794779T3 (fr)
GE (1) GEP20217242B (fr)
HK (1) HK1258157A1 (fr)
HR (1) HRP20200781T1 (fr)
HU (1) HUE049305T2 (fr)
IL (1) IL260923B (fr)
LT (1) LT3419978T (fr)
MA (2) MA52987A (fr)
MD (1) MD3419978T2 (fr)
ME (1) ME03743B (fr)
MX (1) MX2018010236A (fr)
MY (1) MY189118A (fr)
NI (1) NI201800080A (fr)
NZ (1) NZ744349A (fr)
PH (1) PH12018501788A1 (fr)
PL (1) PL3419978T3 (fr)
PT (1) PT3419978T (fr)
RS (1) RS60261B1 (fr)
RU (1) RU2718902C2 (fr)
SG (1) SG11201806307YA (fr)
SI (1) SI3419978T1 (fr)
SV (1) SV2018005726A (fr)
TN (1) TN2018000295A1 (fr)
TW (1) TWI665201B (fr)
UA (1) UA119835C2 (fr)
UY (1) UY37133A (fr)
WO (1) WO2017144995A1 (fr)
ZA (1) ZA201804972B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3419978T3 (da) 2016-02-24 2020-06-02 Pfizer Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
WO2019178079A1 (fr) * 2018-03-12 2019-09-19 Abbvie Inc. Inhibiteurs de la signalisation à médiation par la tyrosine kinase 2
EP3793559A1 (fr) 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Dérivés de dihydropyrazolo pyrazine carboxamide substitués
CA3100731A1 (fr) 2018-05-18 2019-11-21 Incyte Corporation Derives de pyrimidine fusionnes utilises en tant qu'inhibiteurs de a2a/a2b
WO2020010197A1 (fr) 2018-07-05 2020-01-09 Incyte Corporation Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
TW202033198A (zh) 2018-10-17 2020-09-16 美商美國禮來大藥廠 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AU2020256720B2 (en) * 2019-04-12 2022-09-01 PrimeGene (Beijing) Co. Ltd. Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
WO2021048736A1 (fr) 2019-09-11 2021-03-18 Pfizer Inc. Traitement de l'hidradénite avec des inhibiteurs de jak
TW202135816A (zh) * 2019-12-18 2021-10-01 美商輝瑞股份有限公司 以激酶抑制劑治療潰瘍性結腸炎
AU2021248720A1 (en) 2020-04-04 2022-11-03 Pfizer Inc. Methods of treating coronavirus disease 2019
CA3179566A1 (fr) * 2020-04-08 2021-10-14 Pfizer Inc. Formes cristallines de 3-cyano-1-[4-[6-(1-methyl-1h-pyrazo-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, et utilisation associee
CN116568299A (zh) * 2020-09-11 2023-08-08 普尔莫西姆治疗有限责任公司 用于治疗或预防肺动脉高压的组合物和方法
CN112592345A (zh) * 2020-12-07 2021-04-02 嘉兴特科罗生物科技有限公司 一种三氮唑并吡嗪类化合物及其用途
WO2022165530A1 (fr) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Inhibiteurs à petites molécules de kinases inductibles par le sel
US20240156822A1 (en) 2021-03-30 2024-05-16 Pfizer Inc. Methods For Treatment of Vitiligo
CA3236262A1 (fr) 2021-10-25 2023-05-04 Isaac Marx Agents de degradation de tyk2 et leurs utilisations
IL312782A (en) * 2021-11-12 2024-07-01 Soter Biopharma Pte Ltd Pyrizolo's fused ring compound and its use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
HUE028347T2 (en) 2008-06-10 2016-12-28 Abbvie Inc Tricyclic compounds
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2010117787A2 (fr) 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibition de l'enzyme ephb3 kinase
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
RU2012148246A (ru) * 2010-04-14 2014-05-20 Эррэй Биофарма Инк. 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
EP2397482A1 (fr) 2010-06-15 2011-12-21 Almirall, S.A. Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK
CN103987713A (zh) 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
PE20142186A1 (es) 2012-03-28 2014-12-29 Merck Patent Gmbh Derivados biciclicos de pirazinona
MX2016001427A (es) 2013-07-31 2016-08-03 Gilead Sciences Inc Inhibidores de syk.
TW201605811A (zh) 2013-12-11 2016-02-16 阿爾米雷爾有限公司 作為jak抑制劑之吡唑并嘧啶-2基衍生物
EP3137454A1 (fr) * 2014-04-28 2017-03-08 Pfizer Inc. Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
WO2016009028A1 (fr) 2014-07-17 2016-01-21 Valeo Systèmes d'Essuyage Balai plat caréné d'essuie-glace
HUE054371T2 (hu) * 2014-12-05 2021-09-28 Array Biopharma Inc 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok
WO2016119707A1 (fr) 2015-01-29 2016-08-04 Hutchison Medipharma Limited Nouveaux composés hétéroaryliques et hétérocycliques, compositions et procédés
CN113563342A (zh) 2015-02-13 2021-10-29 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
EP3290418B1 (fr) 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Inhibiteurs de janus kinase (jak)
WO2017108723A2 (fr) 2015-12-22 2017-06-29 F. Hoffmann-La Roche Ag Dérivés pyrazolo [1,5 a]pyrimidine en tant que modulateurs d'irak 4
DK3419978T3 (da) 2016-02-24 2020-06-02 Pfizer Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
WO2019034973A1 (fr) 2017-08-14 2019-02-21 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl et dérivés associés

Also Published As

Publication number Publication date
PL3419978T3 (pl) 2020-11-30
US10144738B2 (en) 2018-12-04
US11472809B2 (en) 2022-10-18
HK1258157A1 (zh) 2019-11-08
BR112018015501A2 (pt) 2018-12-18
IL260923B (en) 2022-01-01
CN109071546B (zh) 2021-03-02
RU2018130547A3 (fr) 2020-03-25
US10822341B2 (en) 2020-11-03
WO2017144995A1 (fr) 2017-08-31
US20190071448A1 (en) 2019-03-07
HRP20200781T1 (hr) 2020-07-24
EP3712153A1 (fr) 2020-09-23
EP3419978A1 (fr) 2019-01-02
CA2958490A1 (fr) 2017-08-24
MX2018010236A (es) 2019-01-14
CN109071546A (zh) 2018-12-21
PH12018501788A1 (en) 2019-06-17
TW201741313A (zh) 2017-12-01
UY37133A (es) 2017-09-29
LT3419978T (lt) 2020-06-10
HUE049305T2 (hu) 2020-09-28
DK3419978T3 (da) 2020-06-02
ME03743B (fr) 2021-04-20
EP3419978B1 (fr) 2020-04-15
ES2794779T3 (es) 2020-11-19
MD3419978T2 (ro) 2020-07-31
SI3419978T1 (sl) 2020-08-31
DOP2018000187A (es) 2019-01-31
JP6505956B2 (ja) 2019-04-24
CR20180372A (es) 2018-09-19
EP3712153B1 (fr) 2021-12-01
TWI665201B (zh) 2019-07-11
ECSP18072109A (es) 2018-10-31
SG11201806307YA (en) 2018-09-27
TN2018000295A1 (en) 2020-01-16
AU2017222417A1 (en) 2018-08-02
NI201800080A (es) 2018-11-22
MA43668B1 (fr) 2020-05-29
US20200399281A1 (en) 2020-12-24
CA2958490C (fr) 2024-02-27
AR107714A1 (es) 2018-05-23
PT3419978T (pt) 2020-06-01
RS60261B1 (sr) 2020-06-30
EA035036B1 (ru) 2020-04-20
CY1122949T1 (el) 2021-10-29
US20230045252A1 (en) 2023-02-09
MY189118A (en) 2022-01-26
CO2018008799A2 (es) 2018-09-20
GEP20217242B (en) 2021-04-12
RU2718902C2 (ru) 2020-04-15
KR102128671B1 (ko) 2020-06-30
JP2019510003A (ja) 2019-04-11
SV2018005726A (es) 2018-10-24
ZA201804972B (en) 2019-06-26
UA119835C2 (uk) 2019-08-12
CL2018002358A1 (es) 2018-11-30
CU20180078A7 (es) 2019-02-04
AU2017222417B2 (en) 2020-07-09
NZ744349A (en) 2023-06-30
RU2018130547A (ru) 2020-03-25
CU24511B1 (es) 2021-05-12
KR20180103158A (ko) 2018-09-18
EA201891463A1 (ru) 2019-03-29
US20170240552A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
DK3322706T3 (da) Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
DK3134413T3 (da) Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
MA52593A (fr) 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
IL290419A (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HK1254651A1 (zh) 吡唑並[1，5-a]嘧啶-3-甲酰胺的環醚衍生物
MA46463A (fr) Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret
TH1601003657A (th) อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส